XTL Biopharmaceuticals Ltd. (TLV:XTLB)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
4.300
0.00 (0.00%)
Mar 27, 2025, 4:36 PM IDT
-62.93%
Market Cap 38.78M
Revenue (ttm) 171.00K
Net Income (ttm) -3.93M
Shares Out 881.39M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 326,785
Average Volume 672,061
Open 4.400
Previous Close 4.300
Day's Range 4.300 - 4.400
52-Week Range 4.100 - 12.100
Beta 1.07
RSI 35.48
Earnings Date Mar 26, 2025

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and change... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 5
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol XTLB
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.